Global study sets new risk-based standard to personalize chemotherapy for colon cancer

(American Society of Clinical Oncology) After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy. In an analysis of six clinical trials with over 12,800 patients, three months of chemotherapy was nearly as effective as six months in patients with relatively lower recurrence risk and caused fewer side effects, particularly nerve damage.